🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Rectal Neuroendocrine Tumor

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort NCT07808164n/a2 sites📍 Hanoi📍 Ho Chi Minh City Tam Anh Research Institute · Tests: IHC analysis for ENPP1, cGAS, and FAP expression DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Atezolizumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051n/a1 site📍 Austin Natera, Inc. Evaluation for NCI Surgery Branch Clinical Research Protocols NCT00001823n/a1 site📍 Bethesda National Cancer Institute (NCI) EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors NCT07317505Phase 13 sites📍 Huntersville📍 Dallas📍 Fairfax Conjupro Biotherapeutics, Inc. · Tests: JMT108 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908Phase 22 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study NCT05645510n/a1 site📍 Edmonton University of Alberta Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors NCT07759960NA1 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: UEMR procedure, ESD procedure Genomic Investigation of Unusual Responders NCT03740503n/a1 site📍 Toronto University Health Network, Toronto Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases NCT02185443Phase 21 site📍 São Paulo University of Sao Paulo · Tests: SBRT Risk Factors for Neuroendocrine Neoplasms NCT06282016n/a1 site📍 Nuremberg Bavarian Cancer Registry · Tests: Case-control study (no intervention) A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379Phase 1, Phase 28 sites📍 Beverly Hills📍 Glendale📍 Los Angeles Neonc Technologies, Inc. · Tests: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib The Florida ASCENT Study NCT07042243NA1 site📍 Gainesville University of Florida · Tests: MyCarePulse and ASCENT PN Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial NCT04693377NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy A Study of DEG6498 in Participants With Solid Tumors NCT07244835Phase 13 sites📍 Beijing📍 Beijing📍 Guangzhou Degron Therapeutics Co. · Tests: DEG6498 A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) NCT06028724n/a1 site📍 Aviano Centro di Riferimento Oncologico - Aviano Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons NCT07788729NA8 sites📍 Augsburg📍 Erlangen📍 Regensburg University of Regensburg · Tests: PRISMA-interventions EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. NCT06263088NA1 site📍 Cleveland Case Comprehensive Cancer Center · Tests: EQUITY GI TARGETed Therapy Drug MONITOring in DIGestive Oncology NCT05443087NA29 sites📍 Amiens📍 Auxerre📍 Avignon UNICANCER · Tests: Blood sampling to build population pharmacokinetics model
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy